文献速递慢性肾脏病肾血管病与高血压

降低LDL胆固醇降低心血管风险不依赖炎症状态

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
PubMed 文献 · Kidney Int · 2017-11-14

基于SHARP研究数据,评估C反应蛋白(CRP)与LDL胆固醇水平与血管及非血管结局的关联。结果显示基线CRP和LDL胆固醇升高均与主要血管事件风险增加相关,但辛伐他汀/依折麦布降低LDL胆固醇对主要血管事件的疗效与基线CRP浓度无关。

要点

  • 基线CRP每升高3倍,主要血管事件风险增加28%。
  • 基线LDL胆固醇每升高0.6 mmol/L,主要血管事件风险增加14%。
  • 降低LDL胆固醇的血管获益不依赖基线CRP水平。

核心结论

  • 在慢性肾脏病人群中,降低LDL胆固醇对主要血管事件的相对获益不依赖基线CRP浓度。

研究设计与样本

  • 基于SHARP研究数据的分析,评估循环CRP和LDL胆固醇水平与血管及非血管结局的关联。

主要发现

  • 基线CRP每升高3倍,主要血管事件风险比为1.28(95%CI 1.19-1.38)。
  • 基线LDL胆固醇每升高0.6 mmol/L,主要血管事件风险比为1.14(95%CI 1.06-1.22)。
  • 基线CRP每升高3倍,非血管事件风险比为1.16(95%CI 1.12-1.21)。
  • 基线LDL胆固醇每升高0.6 mmol/L,非血管事件风险比为0.96(95%CI 0.92-0.99)。

关键数值与推荐

  • 主要血管事件定义为非致死性心肌梗死、心源性死亡、卒中或动脉血运重建。
  • 随机比较中,辛伐他汀/依折麦布降低LDL胆固醇对主要血管事件的疗效与基线CRP浓度无关。

临床怎么用

  • 对慢性肾脏病患者决定他汀类治疗应继续基于动脉粥样硬化事件的绝对风险。
  • 绝对风险评估可包括炎症血浆生物标志物,但降低LDL胆固醇的相对获益不依赖CRP浓度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Markers of inflammation, including plasma C-reactive protein (CRP), are associated with an increased risk of cardiovascular disease, and it has been suggested that this association is causal. However, the relationship between inflammation and cardiovascular disease has not been extensively studied in patients with chronic kidney disease. To evaluate this, we used data from the Study of Heart and Renal Protection (SHARP) to assess associations between circulating CRP and LDL cholesterol levels and the risk of vascular and non-vascular outcomes. Major vascular events were defined as nonfatal myocardial infarction, cardiac death, stroke or arterial revascularization, with an expanded outcome of vascular events of any type. Higher baseline CRP was associated with an increased risk of major vascular events (hazard ratio per 3x increase 1.28; 95% confidence interval 1.19-1.38). Higher baseline LDL cholesterol was also associated with an increased risk of major vascular events (hazard ratio per 0.6 mmol/L higher LDL cholesterol; 1.14, 1.06-1.22). Higher baseline CRP was associated with an increased risk of a range of non-vascular events (1.16, 1.12-1.21), but there was a weak inverse association between baseline LDL cholesterol and non-vascular events (0.96, 0.92-0.99). The efficacy of lowering LDL cholesterol with simvastatin/ezetimibe on major vascular events, in the randomized comparison, was similar irrespective of CRP concentration at baseline. Thus, decisions to offer statin-based therapy to patients with chronic kidney disease should continue to be guided by their absolute risk of atherosclerotic events. Estimation of such risk may include plasma biomarkers of inflammation, but there is no evidence that the relative beneficial effects of reducing LDL cholesterol depends on plasma CRP concentration.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Storey BC, Staplin N, Haynes R, et al. Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation. Kidney Int. 2017. PMID: 29146277. doi:10.1016/j.kint.2017.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。